All Q2 FY26 results →

NP

Natco Pharma

Q2 FY26

Natco Pharma Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹785

Market cap₹15.4K Cr

P/E13.5

Updated16 Oct 2026

Read3 min read

The short version

Base business expected to grow at 10-15% annually. Base business expected to grow at 10% to 15% annually.

From Natco Pharma's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Base business expected to grow at 10-15% annually.
Exclusive product launches from 2027-2029 anticipated to drive significant profit jumps, potentially 50-60% in some years.
Growth driven by large opportunities in the US and ROW markets, including multiple products with potential revenues from $25 million up to $150 million.
Stable and improving performance from the ROW business, including South Africa investment contributing 25-30% to base earnings.
Pipeline expected to yield incremental launches, especially from 2027 onwards, with 2026 and early 2027 being relatively slower.

2 more points from Natco Pharma's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

Base business expected to grow at 10% to 15% annually.
Significant profit jumps anticipated in years when exclusivity on products begins, with potential 50% to 60% increases.
Large launches expected mainly in 2027 and 2028, followed by continued growth in 2029.
South Africa business acquisition to contribute 25% to 30% of base earnings, bringing more stability.
Guidance for Q3-Q4 FY26: Rs 750-800 crores revenue per quarter and Rs 135-150 crores PAT per quarter, including Adcock Ingram.
Full-year FY26 PAT guidance around Rs 1,275 to 1,300 crores.

2 more points from Natco Pharma's call on margins

Pro opens every point from 15K+ earnings calls

See what Natco Pharma said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Natco Pharma has completed the acquisition of Adcock Ingram, with plans to add pipeline products and license others, expecting good long-term growth from this asset.
The company is open to new investment opportunities and is actively looking for acquisitions, particularly in the US market if good opportunities arise.
They continue to make small strategic investments (~Rs 40-50 crores annually) in niche, disruptive biotech companies (e.g., eGenesis, CAR-T cell therapy), with openness to increase equity where opportunities arise.
Cash position post-Adcock acquisition is estimated around Rs 2,700-2,800 crores, indicating capacity for further investments.

2 more points from Natco Pharma's call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

Natco Pharma currently has substantial cash even after the Adcock acquisition.
The company is open to new investment opportunities and is actively looking at different options.
They have not disclosed any immediate plans for new fundraising through debt or equity.
Recent acquisitions (e.g., Adcock) were funded through cash and some borrowing (~Rs 400 crores).

2 more points from Natco Pharma's call on fundraising

Pro opens every point from 15K+ earnings calls

See what Natco Pharma said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Natco Pharma expects 10% to 15% growth in its base business over the next five years.
Exclusive product launches starting from 2027-2028 could result in significant jumps, with some years showing 50% to 60% profit growth.
Pipeline opportunities include several with revenue potentials of US$25-30 million and others in the US$100-150 million range.

2 more points from Natco Pharma's call on order book

Pro opens every point from 15K+ earnings calls

Natco Pharma — Quarterly revenue & net profit

Revenue Net profit

Sep 2024Q2 FY25

Dec 2024Q3 FY25

Mar 2025Q4 FY25

Jun 2025Q1 FY26

Sep 2025Q2 FY26

Dec 2025Q3 FY26

Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹647 Cr, net profit ₹151 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Natco Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Natco Pharma and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Natco Pharma Q2 FY26 results?

Base business expected to grow at 10-15% annually. Base business expected to grow at 10% to 15% annually.

What is Natco Pharma share price analysis?

Natco Pharma currently shows a neutral. The stock trades at a P/E of 13.5 with a market cap of ₹15,400 Cr. Investors should review the full earnings analysis for detailed insights.

Is Natco Pharma planning capital expenditure?

Natco Pharma has completed the acquisition of Adcock Ingram, with plans to add pipeline products and license others, expecting good long-term growth from this asset.

Keep Natco Pharma on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.